Neogenomics Inc expected to post a loss of 7 cents a share - Earnings Preview

NeoGenomics

04/11/2023 03:07

* Neogenomics Inc  NEO.OQ   NEO.O  is expected to show a
rise in
quarterly revenue when it reports  results 
    * The Fort Myers Florida-based  company is expected to
report  a
10.0% increase in revenue to $141.648 million from $128.78
million a year ago, according to the mean estimate from 12
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for Neogenomics Inc is
for a
loss of 7 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Neogenomics
Inc
is $18​, above​ its last closing price of $15.27. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.11       -0.11      -0.05     Beat    56
 Mar. 31 2023  -0.15       -0.15      -0.09     Beat    40.5
 Dec. 31 2022  -0.15       -0.16      -0.06     Beat    63.6​
 Sep. 30 2022  -0.20       -0.21      -0.14     Beat    32
 ​​Jun.        -0.20       -0.23      -0.16     Beat    29
 30 2022                                                
 Mar. 31 2022  -0.24       -0.24      -0.20     Beat    15​
 Dec. 31 2021  -0.14       -0.15      -0.14     Beat    3.8
 Sep. 30 2021  -0.09       -0.09      -0.08     Beat    6.5
 This summary was machine generated November 4 at 03:06 GMT.  All
figures in US dollars  unless otherwise stated